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A complex inflammatory reaction takes place inresponse to cardiopulmonary bypass (CPB), occur-
ring in part because of exposure of blood to the extra-
corporeal circuit and occurring in part because of
ischemia-reperfusion of selected tissues. Documented
components of this inflammatory reaction include the
activation of complement,1-3 the increased surface
expression of adhesion molecules on circulating leuko-
cytes,4-6 and the presence of inflammatory cytokines
within the systemic circulation.7-9 One principal
cytokine released into the circulation after CPB is inter-
leukin 6 (IL-6), a pleiotropic molecule with biologic
activity that includes the induction of intercellular adhe-
sion molecule-1 (ICAM-1) expression on cardiac
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myocytes (thus supporting neutrophil-myocyte adhe-
sion),10 the inhibition of apoptosis,11,12 and direct neg-
ative inotropic properties on cardiac myocytes as
well.13,14 The source of IL-6 release into the systemic
circulation after CPB is uncertain; however, the pres-
ence of IL-6 messenger RNA (mRNA) in myocytes
within the border zone of myocardial infarctions after
canine coronary artery occlusion-reperfusion experi-
ments has been documented.15 Until recently, it was
thought that, during CPB, the myocardium would be
protected from inflammatory injury by hypothermia
and cardioplegic arrest. Yet recent studies suggest that
the myocardium may participate in or may be affected
by the inflammatory response to CPB to a greater
extent than previously recognized. Whether IL-6 induc-
tion occurs within the myocardium after CPB is
unknown. It was the purpose of this study to character-
ize the expression of IL-6 and ICAM-1 within the
myocardium after CPB by examining myocardial biop-
sy specimens obtained at different times after the
bypass procedure for the presence of IL-6 and ICAM-1
mRNA. Leukocytes isolated from the peripheral circu-
lation before, during, and after CPB were also exam-
ined for IL-6 mRNA expression.
Methods
Animal preparation.  Healthy adult mixed breed dogs
(16-25 kg) were anesthetized with sodium pentobarbital (30
mg/kg), intubated, and mechanically ventilated with 100%
oxygen. After femoral arterial cannulation, ventilatory rate
and tidal volume were adjusted to establish a normal pH and
PCO2, as determined by arterial blood gas. After midline tho-
racotomy, CPB was achieved by selective venous cannulation
of the inferior and superior venae cavae, with arterial return
directed into the distal aortic arch. The bypass circuit consist-
ed of a cardiotomy reservoir and variable-prime membrane
oxygenator (Cobe Cardiovascular, Inc), a heat exchanger, and
a roller pump (Sarns/3M Healthcare). The circuit was primed
with 40 to 50 mL/kg body weight of lactated Ringer’s solu-
tion. Before CPB, the circuit was demonstrated to be free of
endotoxin by means of Limulus amebocyte lysate assay.
Two groups of animals were included in this study. The
first group, designated the CPB group, consisted of 9 animals
that underwent CPB with an aortic crossclamp time of 60
minutes and total bypass times of approximately 90 minutes.
Before cannulation, each animal was given porcine heparin
sodium, 100 U/kg, for anticoagulation. After the aorta was
crossclamped, potassium cardioplegic solution (Plegisol,
Abbott Laboratories) cooled to 4°C was administered in a
prograde fashion until complete arrest of the heart was
achieved. The animals were cooled to a rectal temperature of
24°C to 28°C. Flow was maintained during bypass at 60 to 70
mL · kg–1 · min–1 at a pressure of 40 to 60 mm Hg. After
rewarming to 37°C and weaning from CPB, animals received
protamine sulfate 1 mg/100 U heparin delivered for reversal
of anticoagulation. Animals were once again ventilated with
100% oxygen. Tidal volume and ventilator rate were set to
optimize pH and PCO2. Animals were then maintained with an
open chest for 3 (n = 4), 6 (n = 4), or 9 (n = 1) hours. At the
end of the reperfusion interval, animals were killed with an
overdose of sodium pentobarbital, and their hearts were
immediately removed for the collection of tissue samples.
Technique was maintained as constant as possible from 1 ani-
mal to the next.
The second group consisted of 4 animals designated as
sham-bypass controls. These animals served as controls in
that they received general anesthesia and mechanical ventila-
tion similar to the animals in group I. In addition, they under-
went midline thoracotomy and cannula placement, but they
were not placed on CPB. Also, these animals were not sub-
jected to cooling and rewarming or hemodilution. These ani-
mals, however, did receive heparin and protamine at a time
and in an amount similar to the CPB animals and were main-
tained with an open chest in a time-matched fashion to those
animals undergoing 3 hours of reperfusion in group I.
Approval. The animal studies in this article were reviewed
and approved by the Baylor College of Medicine Animal
Care and Use Committee. All animals received humane care
in compliance with the “Principles of Laboratory Animal
Care” formulated by the National Society for Medical
Research and the “Guide for the Care and Use of Laboratory
Animals” prepared by the Institute of Laboratory Animal
Resources and published by the National Institutes of Health
(National Institutes of Health publication No. 86-23, revised
1985).
Neutrophil isolation procedure.  Forty milliliters of
whole blood was collected from the experimental animals
into citrate-phosphate-dextrose buffer before CPB, immedi-
ately after CPB, and at 3 hours of reperfusion. Granulocyte
and mononuclear cell (monocyte-lymphocyte) fractions were
isolated on a commercially available single-density gradient
(NIM, Cardinal Assoc, Inc) according to manufacturer’s
instructions.
Northern blot analysis. Myocardial biopsy material was
immediately snap frozen in liquid nitrogen on collection and
stored at –80°C until RNA extraction. RNA extraction was
performed from leukocyte samples immediately after leuko-
cyte isolation. RNA was extracted by the acid guanidinium
phenol chloroform solvent extraction method. Northern
analysis of isolated RNA was subsequently performed with
1% agarose formaldehyde denaturing gels and capillary
transfer to nitrocellulose membranes (Immobilon NC,
Millipore Corporation) by standard procedures. Loading of
RNA was monitored by ethidium bromide staining.
Membranes were prehybridized for 2 hours in buffer contain-
ing 50% formamide; NaCl, 0.8 mol/L; NaPO4, 50 mmol/L;
ethylenediamine tetraacetic acid, 1 mmol/L; 2.5× Denhart
solution; and herring sperm DNA. They were then hybridized
overnight at 58°C in the same buffer containing 3 × 107 cpm
phosphorus 32–labeled antisense transcripts of dog IL-6 and
dog ICAM-1. After being washed, filters were exposed to
Kodak XAR-5 x-ray film, as previously described.
258 Dreyer et al The Journal of Thoracic and
Cardiovascular Surgery
August 2000
RNA template preparation for reverse transcrip-
tase–polymerase chain reaction.  Myocardial tissue sam-
ples were first homogenized in Trizol reagent (Gibco-BRL)
by means of disposable RNase-free pestles (PGC Scientific).
Total RNA was isolated according to the manufacturer’s
instructions.
Reverse transcription and polymerase chain reaction.
Reverse transcription–polymerase chain reaction (RT-PCR)
was used for the detection of transcripts. For the synthesis
of complementary DNA (cDNA), 2 µL of extracted RNA
was mixed with 6 µg (2 µL of 3 mg/mL) of random primers
(Gibco-BRL) and 7.2 µL of diethyl-pyrocarbonate–treated
water in the presence of 0.5 U (0.5 µL) of Prime RNase
inhibitor (5’-3’, Inc). This mixture was heated to 95°C for
5 minutes and then snap-cooled on ice. To this we added 4
µL of 5× reverse transcriptase buffer (Gibco-BRL), 2 µL of
100 mmol/L dithiothreitol, 0.8 µL of 25 mmol/L deoxyri-
bonucleoside triphosphates, another 0.5 µL of RNase
inhibitor, and 200 U (1 µL) of Moloney murine leukemia
virus reverse transcriptase (Gibco-BRL). The samples were
incubated at 37°C for 1 hour, followed by 5 minutes at
95°C to inactivate the enzyme. Two microliters of this first-
strand cDNA was subjected to PCR amplification to detect
β-actin or IL-6 RNA.
To confirm the isolation of RNA from the tissue samples and
confirm that equivalent quantities of RNA were used in each
RT-PCR reaction, we subjected 2 µL of cDNA to PCR with β-
actin–specific primers. The template was amplified in a 20-µL
reaction, containing 1× PCR buffer (Gibco-BRL), 2.5 mmol/L
magnesium chloride, 0.25 mmol/L deoxyribonucleoside
triphosphates, 0.5 µmol/L oligonucleotide primers, and 2.5 U of
Taq DNA polymerase (Gibco-BRL). After an initial 5-minute
incubation at 94°C, 35 rounds of amplification were performed
by means of a Stratagene RoboCycler thermal cycler
(Stratagene) under the following conditions: 94°C for 45 sec-
onds, 64°C for 45 seconds, and 72°C for 45 seconds. This was
followed by a 72°C incubation for 5 minutes.
PCR was used as described for the amplification of β-actin
transcripts to detect IL-6 RNA. All PCR products were
detected by 1.75% agarose gel electrophoresis.
Primers were as follows: IL-6: Ca-IL6-1, CTGGTGATG-
GCTACTGCTTTC; Ca-IL6-2RT, TTTAGCATCTGGAC-
CAGGATC (product = 405 bp) and β-actin: β-ACT-1RT,
TACATGGCTGGGGTGTTGAA; β-ACT-4, CATGGAT-
GATGATATCGCCG (product = 399 bp).
In situ hybridization.  Immediately after collection,
canine myocardial tissue was immersion fixed in B*5
overnight and subsequently embedded in paraffin. Three-
micrometer sections were cut with a Leica microtome (Leica
Microsystems). Sections for in situ hybridization were
hybridized overnight at 42°C with digoxigenin-labeled sense
and antisense IL-6 probes. Detection was performed by using
alkaline phosphatase–conjugated antidigoxigenin antibody.
Results
Northern blot and RT-PCR analysis.  Northern blot
analysis was performed on myocardial tissue samples
looking for induction of both IL-6 and ICAM-1 genes. As
depicted in Fig 1, 3 of the 4 CPB dogs at 3 hours of reper-
fusion and 3 of the 4 CPB dogs at 6 hours of reperfusion
Fig 1.  Northern blot analysis of IL-6 mRNA expression in the myocardium of animals undergoing CPB or in time-
matched sham-bypass control animals (SHAM). Samples from dogs 1 to 4 were obtained 3 hours into recovery after
completion of the bypass procedure. Samples from dogs 5 to 8 were obtained 6 hours into recovery after comple-
tion of CPB. A single animal from 9 hours of reperfusion and two sham-bypass animals are included.
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demonstrated a substantial increase in IL-6 mRNA
expression when compared with sham-bypass control
animals. As demonstrated in Fig 2, ICAM-1 mRNA also
was expressed in the CPB dogs at 3 hours of reperfusion.
The pattern of ICAM-1 expression roughly paralleled
that of IL-6 in that ICAM-1 was most strongly expressed
in dogs 2 and 3, where IL-6 was most strongly expressed
as well. In dogs 1 and 4 ICAM-1 expression was less,
although clearly increased when compared with sham-
bypass control animals. IL-6 was either absent (dog 1) or
less strongly expressed (dog 4) in these dogs as well. At
6 hours of reperfusion, ICAM-1 was minimally
expressed in the CPB dogs and did not parallel IL-6
expression (data not shown).
As depicted in Fig 3, RT-PCR analysis demonstrated
that even with gene product amplification, IL-6 mRNA
was minimally present or not expressed in normal dogs
or in dogs undergoing the sham-bypass procedure. IL-
6 induction was limited to those dogs undergoing CPB
with cardioplegic arrest of the heart.
In contrast to the myocardial tissue samples of dogs
undergoing CPB, Northern blot analysis of circulating
leukocytes, both neutrophils and mononuclear cells,
failed to demonstrate any evidence of IL-6 mRNA
expression at any of the time points tested: before,
immediately after, or 3 hours after CPB. This was true
in 4 of 4 dogs tested (Fig 4).
In situ hybridization. In situ hybridization for IL-6
at 3 hours of reperfusion demonstrated a diffuse trans-
mural staining of cardiac myocytes (Fig 5, A). Note
that this staining pattern occurred largely in the
absence of marginated inflammatory cells. This pattern
Fig 2.  Northern blot analysis of ICAM-1 mRNA expression
in the myocardium of the same animals undergoing CPB with
3 hours recovery, as depicted in Fig 1 (lanes 1-4). Lanes 5
and 6 represent 2 time-matched sham-bypass control animals
(SHAM).
Fig 3.  RT-PCR experiment demonstrating canine myocardial
IL-6 mRNA expression 1, 3, and 6 hours after the completion
of CPB and in a lipopolysaccharide (LPS)-treated positive
control animal. Myocardium from 2 normal uninstrumented
dogs and 2 sham-bypass control dogs (SHAM) failed to
express IL-6 mRNA despite message amplification with the
PCR technique.
Fig 4.  Representative Northern blot analysis of IL-6 mRNA
expression in circulating monocytes-lymphocytes and neu-
trophils (PMN) before CPB (Pre-CPB), at the completion of
CPB (End-CPB), and at 3 hours into recovery after CPB (3 hr
rep), as well as in spleen from a lipopolysaccharide (LPS)-
stimulated positive control animal.
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of staining from animal to animal was consistent with
the results of Northern blot analysis for IL-6 induction,
as described above. In contrast, in situ hybridization
studies in sham-bypass control animals failed to
demonstrate IL-6 induction within the cardiac
myocytes (Fig 5, C).
Discussion
A number of investigators have now documented that
IL-6 is released into the peripheral circulation of
patients undergoing CPB with moderate degrees of
hypothermia. Although the exact time profile of IL-6
release has varied somewhat from study to study, all
Fig 5. Representative IL-6 in situ hybridization results in histologic sections of canine myocardium. A, In situ
hybridization with the antisense canine IL-6 probe in myocardium from a dog reperfused for 3 hours after the com-
pletion of CPB. The blue reaction product is indicative of the presence of IL-6 mRNA within cardiac myocytes. B,
In situ hybridization with the sense canine IL-6 negative control in a serial section from the same animal repre-
sented in A. C, In situ hybridization with the antisense canine IL-6 probe in myocardium from a sham-bypass con-
trol dog time matched to 3 hours of reperfusion after CPB. There is no indication of IL-6 mRNA staining in this
section. D, In situ hybridization with the sense canine IL-6 negative control in a serial section from the same ani-
mal represented in C. Note, all sections were counterstained with eosin.
have demonstrated an increase in plasma IL-6 within a
few hours after the completion of CPB that has persist-
ed out to 24 hours.7-9 The source of this IL-6 produc-
tion, however, has not been conclusively identified. It
has been commonly assumed that circulating inflam-
matory cells activated by exposure to the extracorpore-
al circuit release IL-6 into the peripheral circulation.
However, two recent studies have suggested that the
heart may be a source of IL-6 production after bypass
by demonstrating increased coronary sinus blood levels
of IL-6 relative to that seen in the peripheral circula-
tion.16,17 Neither of these studies identified a tissue
source within the heart that was capable of producing
IL-6, and candidate tissues could include cardiac
myocytes, vascular endothelial cells, or infiltrating
inflammatory cells. Other recent studies have demon-
strated that cardiac myocytes can produce IL-6.
Sawa,17 Yamauchi-Takihara,18 and their colleagues
demonstrated in vitro that IL-6 is increased in the
supernatant of cultured myocytes from Wistar rats
when exposed to hypoxia and reoxygenation. In a sim-
ilar fashion Gwechenberger and associates15 recently
demonstrated that isolated canine myocytes express IL-
6 mRNA in response to a variety of stimuli, including
tumor necrosis factor α (TNF)-α, IL-1β, endotoxin,
and cardiac lymph collected after ischemia-reperfu-
sion. Furthermore, their study documented reperfusion-
dependent expression of IL-6 mRNA in the viable bor-
der zone of a myocardial infarction within 1 hour of
reperfusion. Our study has clearly demonstrated for the
first time the induction of IL-6 in vivo in canine cardiac
myocytes within the first 3 hours of recovery after CPB
and before the presence of a significant inflammatory
infiltrate. We also demonstrated that IL-6 mRNA
induction is not evident in circulating leukocytes
before, during, or within the first 3 hours after the CPB
procedure as commonly believed.
The stimulus for myocyte IL-6 production in this con-
text is unknown, but direct ischemic-hypoxic injury to the
cell with subsequent reperfusion is a possibility. The
extent of myocardial ischemia induced during CPB was
not vigorously explored in this study. Myocardial tem-
perature and pH were not measured directly, nor was
myocardial blood flow measured during aortic cross-
clamping. Nonoxygenated crystalloid cardioplegic solu-
tuion was used in this study rather than blood cardio-
plegic solution, and the extent to which this may have
affected myocardial oxygenation is uncertain. There
appeared to be variability between CPB animals in
the expression of both IL-6 and ICAM-1 mRNA, and
the extent to which variation in the ischemic insult to the
myocardium of these animals may have contributed to
this observed difference remains speculative.
Alternatively, IL-6 induction could have occurred
because of the local release of an upstream inflamma-
tory cytokine. In coronary artery occlusion-reperfusion
experiments, resident cardiac mast cells have been
demonstrated to release TNF-α,19 and as discussed
above, TNF-α has been demonstrated to stimulate the
induction of IL-6 in isolated cardiac myocytes in vitro.
Also, recent evidence from rats suggests that the induc-
tion of nuclear factor κB occurs in the myocardium
subjected to occlusion-reperfusion. IL-6 is known to
have a κB response element, and an increase in IL-6
could, in part, be due to the upstream induction of
nuclear factor κB.20
The fact that IL-6 is produced by cardiac myocytes in
the context of CPB raises interesting questions as to its
physiologic significance, pathophysiologic signifi-
cance, or both. Despite the documentation of high lev-
els of IL-6 in the plasma after CPB, its role remains
largely unknown. Several important possibilities, how-
ever, do exist. In this study we documented that ICAM-
1 mRNA was increased within the first 3 hours after
CPB along with IL-6 expression, suggesting a possible
relationship between the two. This observation is
important because studies by Youker,10 Smith,21
Entman,22 and their coworkers have demonstrated that
neutrophil-induced oxidative injury to cardiac
myocytes is dependent on neutrophil-myocyte adher-
ence mediated by neutrophil CD18 expression and
myocyte ICAM-1 expression. In vitro cardiac myocyte
ICAM-1 expression can be affected by a variety of
cytokines, including IL-1, TNF-α, and IL-6. IL-6, how-
ever, appears to be the physiologically relevant
cytokine as the ability of postischemic cardiac lymph
to induce myocyte ICAM-1 expression was completely
inhibited by a neutralizing antibody to human IL-6.
Also, leukocyte-mediated injury to the myocardium
after CPB appears to be a relevant mechanism of
myocardial dysfunction after CPB as post-CPB leuko-
cyte depletion appears to enhance left ventricular sys-
tolic function.23
IL-6 may also contribute to myocardial stunning post-
operatively. Finkel and associates13 have demonstrated
that the addition of recombinant human IL-6 to the medi-
um bathing isolated hamster papillary muscles resulted in
a concentration-dependent, reversible, negative inotropic
effect that was blocked by the administration of the nitric
oxide synthase inhibitor N-monomethy-L-arginine. Also,
a role for cytokine-inducible nitric oxide synthase in car-
diac myocytes has been implicated as a mechanism of
myocardial contractile dysfunction associated with the
systemic inflammatory response syndrome14 and associ-
ated with myocardial infarction.24 Finally, one study, per-
formed in 3-week-old piglets, suggests that the L-argi-
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nine–nitric oxide pathway is also of pathophysiologic
significance to the development of myocardial dysfunc-
tion after CPB.25
Yet one must consider what selective advantage
myocardial IL-6 production might have to the
myocardium. As an alternative action to the potential
mechanisms of myocyte injury detailed above, IL-6
could prove to have a cardioprotective role after CPB
by inhibiting cardiac myocyte apoptosis. Apoptosis
has recently been recognized as a mechanism of
myocyte death in the failing myocardium associated
with chronic congestive heart failure.26 In addition,
apoptosis has been identified as a mechanism of
myocyte loss in acute ischemia and reperfusion
injury in the rabbit heart27 and in cultured neonatal
rat cardiomyocytes exposed to hypoxia.28 Little is
known about the induction of apoptosis in the
myocardium protected by hypothermic cardioplegic
arrest during CPB; however, a recent study by Aebert
and colleagues29 demonstrated histopathologic evi-
dence of DNA fragmentation by nick end labeling
consistent with apoptosis in atrial biopsy specimens
from patients undergoing CPB with cardioplegic
arrest and moderate hypothermia. His study also
demonstrated, by Northern blot analysis, induction of
the protooncogenes c-fos and c-jun, which may act as
transcription factors for other genes involved in the
apoptotic pathway. Whether IL-6 has a regulatory
role in the apoptotic pathway of cardiac myocytes is
presently unknown, although IL-6 appears to be pro-
tective against apoptosis in other cell types.11,12 In
addition, a novel cardiac cytokine, cardiotrophin 1,
has recently been described and appears to promote
cardiac myocyte survival by activation of an anti-
apoptotic signaling pathway. Cardiotrophin 1 is a
member of the IL-6 family of cytokines, all of which
exert their biologic effects through the shared signal-
ing subunit gp130.30 Whether cardiotrophin 1 and IL-
6 share an antiapoptotic effect in the myocardium is
at present unknown.
In summary, what is known from this study is that
CPB with cold cardioplegic arrest appears to be a suf-
ficient stimulus to induce IL-6 synthesis in cardiac
myocytes. Although the exact mechanism of induction
and the role that IL-6 performs in the postoperative set-
ting requires further investigation, it appears that the
local production of IL-6 could play a pivotal role in the
regulation of myocardial function postoperatively.
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